Ebene Magazine – Crocs, Inc. (NASDAQ: CROX) is expected to have revenue of $ 414.52 million this quarter

0
32
Ebene Magazine - Crocs, Inc. (NASDAQ: CROX) is expected to have revenue of $ 414.52 million this quarter

Sign up for MarketBeat All Access to get access to all of MarketBeat’s research tools:

Wall Street brokers expect Crocs, Inc. (NASDAQ: CROX) to be available for the current fiscal quarter, according to Zacks will generate sales of $ 414.52 million. Five analysts have published estimates of Crocs’ earnings. The lowest revenue estimate is $ 410.00 million and the highest is $ 421.80 million. Crocs posted sales of $ 281.16 million for the same quarter last year, representing a positive growth rate of 47.4% year over year. The company is expected to announce its next quarterly results on Thursday, April 22nd.

On average, analysts expect Crocs to post total annual sales of $ 1.72 billion for the current year, with estimates between $ 1.71 and $ 1.76 billion. For the next fiscal year, analysts forecast sales of 1.84 billion US dollars, with estimates ranging between 1.76 and 1.92 billion US dollars. Zacks’ average revenue is based on a survey of research analysts covering Crocs.

Crocs (NASDAQ: CROX) last released its results on Monday, February 22nd. The textile maker reported earnings per share of $ 1.06 for the quarter, beating the consensus estimate of $ 0.79 by $ 0.27. Crocs had a net margin of 12.08% and a return on equity of 102.93%. The company posted revenue of $ 411.50 million for the quarter, compared to the consensus estimate of $ 408.71 million. For the same period last year, the company posted earnings of $ 0.12 per share. The company’s quarterly revenue increased 56.5% year over year.

CROX has been the subject of several analyst reports. OTR Global initiated coverage of Crocs stocks in a research note on Thursday, January 7th. They gave the stock a « positive » rating. Pivotal Research raised its target price on Crocs stock from $ 92.00 to $ 100.00 and rated the company as a « Buy » in a report on Thursday, February 25th. Monness Crespi & Hardt raised its target price on Crocs stock from $ 60.00 to $ 91.00 and rated the company as a « Buy » in a report on Wednesday, January 13th. B. Riley reiterated his buy recommendation and announced in a report on Wednesday, February 24th, a price target of USD 93.00 (previously USD 87.00) on Crocs shares. Finally, UBS Group raised its target price on Crocs shares from USD 75.00 to USD 85.00 and gave the company a « neutral » rating in a report on Wednesday, February 17th. They discovered that the move was a rating call. Three equity analysts have rated the stock with a hold rating, eight with a buy rating and one with a strong buy rating. Crocs has an average Buy rating and a consensus target of $ 78.70 (adsbygoogle = window.adsbygoogle || []). Push ({});

NASDAQ CROX shares opened at $ 80.53 on Tuesday. The company has a quick rate of 1.07, a current rate of 1.70, and a leverage ratio of 0.59. Crocs has a 52-week low of $ 8.40 and a 52-week high of $ 84.09. The company’s 50-day moving average is $ 76.43 and the 200-day moving average is $ 58.43. The company has a market cap of $ 5.27 billion, a value for money of 36.77, a PEG ratio of 1.35, and a beta of 1.77.

In other news, CEO Andrew Rees sold 5,100 shares in the company in a transaction on Thursday, January 7th. The shares were sold at an average price of $ 70.12 for a total transaction of $ 357,612.00. Following the sale, the chief executive officer now owns 849,848 shares in the company valued at approximately $ 59,591,341.76. The sale was disclosed in a document filed with the SEC, which can be accessed via this link. In the past 90 days, insiders have sold 80,000 shares in the company, valued at $ 6,087,902. Company insiders own 2.32% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold CROX shares. Samlyn Capital LLC took a new position in Crocs stock valued at approximately $ 66,841,000 during the third quarter. BlackRock Inc. added 10.9% to its position in Crocs stocks in the fourth quarter. BlackRock Inc. now owns 10,862,273 shares in the textile maker valued at $ 680,630,000 after purchasing an additional 1,067,955 shares last quarter. Lord Abbett & CO. LLC took a new position in Crocs stock valued at approximately $ 44,824,000 during the 3rd quarter. Morgan Stanley added 270.8% to its position in Crocs stocks in the fourth quarter. Morgan Stanley now owns 797,854 shares in the textile maker valued at $ 49,993,000 after buying an additional 582,682 shares last quarter. Eventually, the Canada Pension Plan Investment Board acquired a new position in Crocs stock valued at approximately $ 34,119,000 in the fourth quarter. 95.34% of the shares are owned by hedge funds and other institutional investors.

Crocs, Inc, together with its subsidiaries, designs, develops, manufactures, markets and sells casual shoes and accessories for men, women and children worldwide. It offers a variety of footwear products including clogs, sandals, flips and slides, shoes and boots under the Crocs brand.

This instant message alert was generated through narrative science technology and financial data from MarketBeat to give readers the fastest, most accurate coverage. This story has been reviewed by the editorial staff of MarketBeat prior to publication. Please send questions or comments about this story to [email protected]

There are more than 200 healthcare companies trading on public markets. With the sheer number of drug companies, medical research companies, hospital systems, and other healthcare stocks, it can be difficult to identify which healthcare companies will outperform the market.

Fortunately, Wall Street’s brightest minds have already done this for us. Every year analysts make around 3,000 different recommendations for healthcare companies. Analysts don’t always get correct « buy » ratings, but it pays to take a close look when multiple analysts from different brokers and research firms give the same health care stock « strong buy » and « buy » ratings.

This slideshow lists the 15 healthcare companies with the highest average analyst recommendations from Wall Street stock analysts over the past 12 months.

Fill out the form below to get the latest headlines and analyst recommendations for your stocks with our free daily email -Receive Newsletters:

Sign up to MarketBeat All Access to get access to all of MarketBeat’s research tools:

View the latest news, buy / sell ratings, SEC filings and insider deals for Your shares. Compare your portfolio performance against leading indices and get personalized stock ideas based on your portfolio.

Get stock ideas daily with the best Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. See what stocks are up to date on social media with MarketBeat’s Trending Stock Report.

Identify stocks that match your criteria using seven unique stock screeners. See what’s happening in the market with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access Stock Screener, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Would you like to see which stocks are moving? View our full range of financial calendars and market data tables for free.

Receive free world class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat enables individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, company buybacks, dividends, earnings, business reports, financial data, insider trading, IPOs, SEC filings, or stock splits, MarketBeat has the objective information you need to analyze stocks. Learn more.

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St # 105, Sioux Falls, SD 57103 | [Email protected] | (844) 978-6257
MarketBeat does not provide financial advice or make recommendations or offers to buy stocks or sell any securities. Learn more.
Don’t sell my information

© 2021 The market data provided will be delayed by at least 10 minutes and hosted by Barchart Solutions. The information is provided « as is » and is provided for informational purposes only, not for commercial or advisory purposes, and is delayed. Please refer to the disclaimer for all delays and terms of use for exchanges. Basic company data from Zacks Investment Research. As a bonus for subscribing to our e-mail newsletters, you will also receive a free subscription to the Liberty Through Wealth e-newsletter. You can unsubscribe at any time.

Enter your email address below to receive a quick daily summary of upgrades, downgrades, and new coverage from Analysts with MarketBeat.com’s FREE daily email newsletter.

Ref: https://www.marketbeat.com

QU’EN PENSEZ-VOUS?

[comment]

Laisser un commentaire, votre avis compte!

[gs-fb-comments]

Laisser un commentaire, votre avis compte!

Laisser un commentaire, votre avis compte!